Compare EME & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EME | RPRX |
|---|---|---|
| Founded | 1987 | 1996 |
| Country | United States | United States |
| Employees | 25000 | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7B | 28.4B |
| IPO Year | 1994 | 2020 |
| Metric | EME | RPRX |
|---|---|---|
| Price | $681.08 | $66.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $940.50 | $65.38 |
| AVG Volume (30 Days) | 384.6K | ★ 3.0M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | 0.24% | ★ 1.40% |
| EPS Growth | ★ 30.99 | N/A |
| EPS | ★ 24.93 | 0.71 |
| Revenue | ★ $16,986,422,000.00 | $2,378,193,000.00 |
| Revenue This Year | $21.88 | $47.40 |
| Revenue Next Year | $12.68 | $9.10 |
| P/E Ratio | ★ $27.26 | $94.74 |
| Revenue Growth | ★ 16.62 | 5.06 |
| 52 Week Low | $564.92 | $36.03 |
| 52 Week High | $951.96 | $67.71 |
| Indicator | EME | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.03 | 73.14 |
| Support Level | $631.70 | $55.48 |
| Resistance Level | $768.75 | N/A |
| Average True Range (ATR) | 27.07 | 1.32 |
| MACD | -2.44 | 0.67 |
| Stochastic Oscillator | 34.73 | 90.98 |
EMCOR Group Inc is a specialty contractor in the United States and a provider of electrical and mechanical construction and facilities services, building services, and industrial services. Its services are provided to a broad range of commercial, technology, manufacturing, industrial, healthcare, utility, and institutional customers through approximately 100 operating subsidiaries. The company's operating subsidiaries are organized into reportable segments: United States mechanical construction and facilities services, which derives key revenue; United States electrical construction and facilities services; United States building services; United States industrial services; and United Kingdom building services. Geographically, its key revenue is derived from the United States.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.